Eli Lilly has surpassed $20 billion in acquisitions in 2026 — a company record — as AI tools compress drug development timelines and reshape how global pharma firms value early-stage assets.1
Key deals include Kelonia Therapeutics at $7 billion, Centessa Pharmaceuticals at $7.8 billion, and three vaccine developers totaling $3.8 billion.1
The strategic logic is AI. Machine learning platforms are accelerating pre-clinical validation globally, raising the price of pipeline assets that once carried prohibitive risk.1 Acquirers can now evaluate molecules faster — and earlier.
Lilly's urgency has historical roots. The Prozac patent cliff in the 2000s triggered years of revenue decline.1 That experience hardwired pipeline risk management into the company's strategy. Facing another potential cliff, Lilly is deploying external capital rather than waiting on internal R&D.
The acquisition-over-R&D logic is visible across the industry. Roche, AstraZeneca, and Novo Nordisk have all expanded deal activity in recent years. But Lilly's $20 billion-plus in a single year sets a new pace — treating deal flow as the primary discovery engine, not a supplement to it.
AI reduces friction in this model. Lower evaluation costs and faster science integration allow earlier-stage bets without absorbing full pre-clinical failure risk.1 The assets Lilly is acquiring are earlier and more numerous than in previous cycles.
For biotech ecosystems in Boston, London, Basel, and Singapore, the shift matters. AI-native startups now attract acquisition interest far earlier — compressing the timeline from founding to exit and redirecting global venture capital toward discovery platforms over late-stage clinical assets.
Whether the strategy pays depends on execution. The signal to watch: if Lilly's internal R&D falls as a share of revenue while acquisition activity holds, the company will have structurally outsourced its discovery engine to AI-native biotechs globally.1
Peers with lower deal activity — across the US, Europe, and Asia — provide a natural comparison. If Lilly's pipeline outperforms theirs, it validates the thesis that AI-era acquisitions can outperform traditional R&D investment at scale.1
